French Observatory of Rare Malignant Tumors of the Ovary

Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)

NCT01304043•ARCAGY/ GINECO GROUP

View on ClinicalTrials.gov

Summary

To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.

Detailed Description

* to establish prognosis factors for the disease * to proceed in a centralised examination of histologic laminas * to reach in the long-term and homogenous follow-up of the patients * to follow-up the long-term toxicities of the treatments given * to analyse and follow-up the later fertility of the patients * to evaluate the interest of setting a multi-disciplinary discussion forum on the Web

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•age \> 18 years old
•germinal or sexual cords ovary tumors histologically proven
•first line or relapse treatment
•written informed consent

Exclusion Criteria

•mental ineptitude to understand and follow the study

Locations (1)

Oncologie, Hôtel-Dieu, 1 place du parvis Notre-Dame

Paris, France

Key Dates

Start Date

January 1, 2002

Completion Date

June 1, 2011

Last Updated

April 20, 2012

Enrollment

204

ACTUAL participants

Conditions

Ovarian Tumors

Interventions

chemotherapies protocols

DRUG

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161

Ovarian Tumors

View study

UNKNOWN

International Ovarian Tumour Analysis (IOTA) Phase 5

NCT01698632

Adnexal MassesOvarian Cysts+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions